Control Bionics Ltd
Control Bionics Limited is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses, such as Motor Neurone Disease and Amyotrophic Lateral Sclerosis.
The business
Control Bionics Limited is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses, such as Motor Neurone Disease and Amyotrophic Lateral Sclerosis. Its products include Control Bionics Trilogy Systems, NeuroStrip, NeuroNode, Cosmos Connect and accessories. NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as electromyography output. This output is then sent wirelessly via NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse and the NeuroNode acts like a mouse button. It is commercializing its advancement in its technology, NeuroStrip. It is focused on neuromuscular rehabilitation and athletic optimization.
Small Caps Research
No research on Control Bionics Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise CBL based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Control Bionics’ US sales and revenue growth fuels strong start to FY25
Australian medical device company Control Bionics (ASX: CBL) is expecting US revenue for the first six months of the 2025 financial year to increase by more than 15% on the previous corresponding period. The anticipated performance reflects increasing demand for the company’s artificial intelligence-based solutions, growing market penetration and a new Healthcare Common Procedure Coding […]
Control Bionics expands NeuroStrip presence into US and Japan with new agreements
Control Bionics (ASX: CBL) has expanded into the US sports performance and Japanese neurological rehabilitation markets with the first commercial agreements for its advanced NeuroStrip wireless wearable device. The strategic partnerships are with existing customers and will leverage the technology to drive better sports performance and patient outcomes, providing platforms for expansion into other regions. […]
Control Bionics gains official US approval for NeuroNode as reimbursable medical device
Control Bionics (ASX: CBL) has announced that the US Centers for Medicare & Medicaid Services (CMS) have approved a new healthcare common procedure coding system (HCPCS) that identifies the NeuroNode wireless and wearable sensor as a reimbursable medical device. NeuroNode has been created for patients with degenerative neurological diseases, spinal cord injuries, cerebral palsy and […]
Control Bionics prepares for Australian launch of DROVE autonomous wheelchair module
An autonomous wheelchair module developed by Control Bionics (ASX: CBL) will be launched on the local market after being listed on the Australian register of therapeutic goods. The DROVE mobility solution is now classified as a Class 1 medical device following approval by the Therapeutic Goods Administration. This status comes after 12 months of extensive […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.